Zydus Cadila stock moves up with USFDA approval for hypertension drug
DSIJ Intelligence / 24 Aug 2017
Zydus Cadila has received final approval from the USFDA to market Candesartan Cilexetil Tablets USP 4 mg, 8 mg, 16 mg and 32 mg, which are used to treat high blood pressure (hypertension) in adults, said the company in a BSE filing on Thursday.
Zydus Cadila has received final approval from the USFDA to market Candesartan Cilexetil Tablets USP 4 mg, 8 mg, 16 mg and 32 mg, which are used to treat high blood pressure (hypertension) in adults, said the company in a BSE filing on Thursday. The drug will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04. Meanwhile, the scrip was trading higher at Rs 498.45 per share, up by Rs 35.95 or 7.77% as at 1220 hours on Thursday, on the BSE. The stock witnessed a spurt in volume by more than 1.62 times and hit an intraday high and low of Rs 503.90 and Rs 465.75, respectively. It attracted a traded volume of 30,16,776 shares and traded value of Rs 14,811.77 lakhs on the NSE.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.